Keywords: Alzheimer's Disease, Spectroscopy, Metabolomics, metabolomic imaging, nuclear magnetic resonance, neurodegeneration, small animals
Motivation: Alzheimer’s disease (AD) diagnosis currently relies on clinical evaluation, and definitive disease characterization can only be accomplished from tissue pathology during autopsy.
Goal(s): Evaluations of AD metabolomics using nuclear magnetic resonance (NMR) spectroscopy to identify potential biomarkers that can differentiate AD from non-AD conditions.
Approach: We collected cortex, hippocampus, and blood samples from mice with and without AD, followed by NMR analysis.
Results: NMR could differentiate between AD and wild-type (WT) conditions for all tissue types, and metabolomic differences in several spectral regions were observed across disease conditions, leading to the identification of potential contributing metabolites and metabolic pathways.
Impact: HRMAS NMR-based metabolomic evaluations can differentiate mice with and without Alzheimer’s disease (AD), characterize metabolic states within brain and blood samples, and identify possible AD biomarkers. It has potential for in vivo implementation and may improve AD diagnosis in clinic.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords